SG11201908160VA - Composition for skin aging measurement, prevention, or alleviation, using hapln1 - Google Patents

Composition for skin aging measurement, prevention, or alleviation, using hapln1

Info

Publication number
SG11201908160VA
SG11201908160VA SG11201908160VA SG11201908160VA SG 11201908160V A SG11201908160V A SG 11201908160VA SG 11201908160V A SG11201908160V A SG 11201908160VA SG 11201908160V A SG11201908160V A SG 11201908160VA
Authority
SG
Singapore
Prior art keywords
skin aging
haplni
protein
alleviating
composition
Prior art date
Application number
Inventor
Dae Kyong Kim
Zhicheng Fu
Moon Jung Back
Original Assignee
Haplnscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haplnscience Inc filed Critical Haplnscience Inc
Publication of SG11201908160VA publication Critical patent/SG11201908160VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present disclosure relates to HAPLNI protein of an aged individual. The HAPLNI protein exhibits reduced expression with aging, and when administered, its effect in alleviating and reversing skin aging including wrinkles is excellent. Therefore, by exploiting the difference in expression, provided are a biomarker composition for measuring skin aging, capable of diagnosing skin aging; a kit; and a method of screening for skin aging alleviating agents, comprising detecting the expression level of HAPLN protein or HAPLNI gene. In addition, provided are a pharmaceutical composition, cosmetic composition, or health functional food for preventing or alleviating skin aging, and a cosmetic composition or health functional food for alleviating wrinkles, each containing any one or more selected from the group consisting of HAPLNI protein, a gene encoding the same, and an effective agent for promoting the expression or activating the functions of HAPLNI protein or gene. 18
SG11201908160V 2017-03-06 2017-03-06 Composition for skin aging measurement, prevention, or alleviation, using hapln1 SG11201908160VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2017/002395 WO2018164290A1 (en) 2017-03-06 2017-03-06 Composition for skin aging measurement, prevention, or alleviation, using hapln1

Publications (1)

Publication Number Publication Date
SG11201908160VA true SG11201908160VA (en) 2019-10-30

Family

ID=63448272

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908160V SG11201908160VA (en) 2017-03-06 2017-03-06 Composition for skin aging measurement, prevention, or alleviation, using hapln1

Country Status (16)

Country Link
US (1) US11202749B2 (en)
EP (1) EP3594685A4 (en)
JP (1) JP2020514739A (en)
CN (1) CN110603448A (en)
AU (1) AU2017403257B2 (en)
BR (1) BR112019018469A2 (en)
CA (1) CA3055168C (en)
CO (1) CO2019009796A2 (en)
IL (1) IL269126B (en)
MX (1) MX2019010533A (en)
NZ (1) NZ756946A (en)
PE (1) PE20191707A1 (en)
RU (1) RU2750486C2 (en)
SG (1) SG11201908160VA (en)
WO (1) WO2018164290A1 (en)
ZA (1) ZA201905864B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020175721A1 (en) * 2019-02-28 2020-09-03 주식회사 하플사이언스 Composition, for preventing, relieving or treating cartilage-related diseases or symptoms, comprising hapln1
KR102166453B1 (en) * 2020-02-03 2020-10-15 중앙대학교 산학협력단 Composition for preventing or treating pulmonary diseases comprising hapln1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6156114A (en) * 1984-08-27 1986-03-20 Kanebo Ltd Cosmetic for preventing skin aging
DE10100121A1 (en) * 2001-01-03 2002-08-01 Henkel Kgaa Method for determining skin stress or skin aging in vitro
GB0422525D0 (en) * 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
WO2007027509A2 (en) * 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
US7908090B2 (en) * 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
WO2008013934A2 (en) * 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
KR20090127153A (en) * 2007-04-06 2009-12-09 겐자임 코포레이션 Methods of evaluating cells and cell cultures
KR100921971B1 (en) * 2007-10-24 2009-10-15 한국과학기술연구원 A composition comprising Chamaenerion angustifolium extract as an active ingredient
US20140163118A1 (en) * 2011-05-03 2014-06-12 Dermachip Inc. Expression Signatures of Genes and Gene Networks Associated with Skin Aging
EP2924432B1 (en) * 2011-05-17 2017-07-05 Chanel Parfums Beauté Screening of hs6st2 activators for preventing and/or attenuating skin ageing and/or hydrating skin
DE102011085497A1 (en) * 2011-10-31 2013-05-02 Evonik Industries Ag Cosmetic formulation
WO2013129456A1 (en) * 2012-02-29 2013-09-06 ロート製薬株式会社 Composition capable of promoting proliferation of fibroblast
JP6185549B2 (en) * 2012-03-16 2017-08-23 ソウル大学校産学協力団Ｓｎｕ Ｒ＆Ｄｂ Ｆｏｕｎｄａｔｉｏｎ Novel TRPV1-inhibiting peptide and composition for preventing skin aging or improving wrinkle containing the same
KR101794396B1 (en) * 2012-05-02 2017-11-06 미쯔비시 케미컬 주식회사 Probe or probe set for evaluating influence of ultraviolet ray on skin, and nucleic acid microarray
US20160192689A1 (en) * 2013-07-31 2016-07-07 Wikifoods, Inc. Encapsulated functional food compositions
GB201505520D0 (en) * 2015-03-31 2015-05-13 Univ Lancaster Composition
KR101897340B1 (en) * 2015-09-09 2018-09-13 중앙대학교 산학협력단 Composition for diagnosing, preventing or improving aging of skin using HAPLN1

Also Published As

Publication number Publication date
CA3055168A1 (en) 2018-09-13
ZA201905864B (en) 2021-10-27
JP2020514739A (en) 2020-05-21
CO2019009796A2 (en) 2019-09-18
PE20191707A1 (en) 2019-11-28
WO2018164290A1 (en) 2018-09-13
MX2019010533A (en) 2019-12-19
RU2019131360A3 (en) 2021-04-07
EP3594685A1 (en) 2020-01-15
NZ756946A (en) 2022-07-01
BR112019018469A2 (en) 2020-04-14
US20200000700A1 (en) 2020-01-02
CA3055168C (en) 2022-09-06
RU2019131360A (en) 2021-04-07
CN110603448A (en) 2019-12-20
AU2017403257A1 (en) 2019-09-26
IL269126B (en) 2021-01-31
US11202749B2 (en) 2021-12-21
AU2017403257B2 (en) 2021-09-30
EP3594685A4 (en) 2020-11-18
RU2750486C2 (en) 2021-06-28

Similar Documents

Publication Publication Date Title
Suetta et al. Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy
BR122020006907B8 (en) ANTI-KRAS SINGLE DOMAIN ANTIBODY AND ITS USE, IN VITRO METHODS FOR MEASURING SAID ANTIBODY LEVELS AND FOR DIAGNOSING A DISORDER MEDIATED BY AN INTRACELLULAR COMPONENT, ISOLATED POLYPEPTIDE, AND COMPOSITION COMPRISING SUCH ANTIBODY OR ISOLATED POLYPEPTIDE
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
BR112015022934A2 (en) neuroactive steroids, compositions, and use thereof
MX2018009738A (en) Anti-dengue virus ns1 protein monoclonal antibodies.
BR112016009099A2 (en) METHOD FOR DETERMINING WHETHER A TEST SUBJECT HAVING A METABOLIC DISORDER IS A CANDIDATE FOR TREATMENT WITH AN FGF19 VARIANT, METHOD FOR DETERMINING WHETHER A FGF19 VARIANT IS A CANDIDATE FOR TREATMENT IN A TEST SUBJECT, USE OF AN FGF19 VARIANT, MODEL FOR DETERMINING IF AN FGF19 VARIANT IS A CANDIDATE FOR PREVENTING A DISEASE
BR112012028648A2 (en) cosmetic use of n-substituted sulfonyloxybenzylamines and related compounds
BR112019000849A2 (en) antibacterial system cleaning compositions and method of manufacture thereof
EA201690159A1 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
BR112015015864A2 (en) pharmaceutical composition, method of preparing a pharmaceutical composition, method of treating an individual with a severe pain condition, and use of a pharmaceutical composition
SG11201908160VA (en) Composition for skin aging measurement, prevention, or alleviation, using hapln1
SG10201901713RA (en) Extracellular matrix compositions
MX347871B (en) Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate.
WO2014058976A3 (en) Biomarkers predictive for clinical response for glatiramer acetate
EA201591773A1 (en) MACRO CYCLIC INHIBITORS RIP2-KINASE
MX2018013865A (en) Probiotic cosmetic compositions and use of the probiotic cosmetic compositions.
FR2949782B1 (en) TRANSGLUTAMINASE ACTIVATOR PEPTIDE AND COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING SAME.
MX2021014822A (en) Improvements in or relating to organic compounds.
WO2019107831A3 (en) Composition for preventing or improving intrinsic aging comprising paeoniflorin or albiflorin
MX2015017535A (en) Treatment of insulin resistance through inhibitors of transcription factor tsc22d4.
BR112015022275B8 (en) PIGMENTED COMPOSITIONS FOR SKIN TREATMENT
EP3555621A4 (en) Test panel to measure blood neurotoxin levels in prematernal women and for the general public in relation to mental disorders of the aging
MA53171A (en) COMPOSITION CONSISTING OF GLYCYRRHIZINE AND ITS COSMETIC AND PHARMACEUTICAL USES
BR112015005904A2 (en) compositions containing beta-hydroxy-beta-methylbutyric acid and use thereof
CL2019002552A1 (en) Composition for the measurement, prevention or relief of skin aging using hapln1.